Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia

NCT06045299 is registered in ClinicalTrials.gov with Corxel Pharmaceuticals as lead sponsor.

NCT NCT06045299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06045299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
Lead sponsor
Corxel Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
September 27, 2023
Completion date
January 27, 2025
Enrollment
300 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

eye diseases, miosis, near vision, presbyopia